Metronidazolo Bioindustria Lim (Metronidazole)

Metronidazole is reduced inside anaerobic microorganisms to generate nitro radical anions. These reactive species damage DNA and inhibit nucleic acid synthesis, leading to bacterial and protozoal cell death. The selective activation in low‑oxygen environments provides targeted antimicrobial activity while sparing most human cells.

The dosing regimen for Metronidazolo Bioindustria Lim is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and adjust the dose as needed.

Safety data for metronidazole during pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only when the potential benefits justify the potential risks to the fetus. Caution is also advised during breastfeeding, as the drug can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Metronidazole belongs to the nitroimidazole class and offers broad activity against anaerobes and certain protozoa. Compared with alternatives such as tinidazole, it has a similar spectrum but a shorter half‑life, requiring more frequent dosing. Compared with clindamycin, metronidazole provides better coverage of protozoal infections and has a lower risk of Clostridioides difficile colitis.

Store the product at below 25 °C in its original packaging, protecting it from moisture and direct light. Do not freeze the solution. Ensure the container is sealed when not in use and handle according to standard aseptic techniques for intravenous medications.

Metronidazolo Bioindustria Lim is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and administered over a period specified by the prescriber, often 30‑60 minutes, depending on the clinical indication and patient tolerance.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare dermatologic conditions like Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, skin changes, and signs of hypersensitivity throughout therapy.

Metronidazolo Bioindustria Lim is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazoles. Caution is advised for patients with severe hepatic impairment, those in the first trimester of pregnancy, and patients receiving concurrent neurotoxic drugs without appropriate monitoring.